Molybdenum's Role as an Essential Element in Enzymes Catabolizing Redox Reactions: A Review.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms and clinical associations without primary data or systematic synthesis
PubMed 39062583 · doi:10.3390/biom14070869
What was done
Narrative review summarizing published literature on human molybdenum-containing enzymes—xanthine oxidase (XO), aldehyde oxidases (AOs), sulfite oxidase (SOX), and mitochondrial amidoxime-reducing component (mARC)—and their biological roles in redox reactions, drug metabolism, and liver pathologies.
What was found
The abstract reports no quantitative data or effect sizes. It qualitatively summarizes that XO contributes to oxidative stress in purine catabolism and correlates with non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC); AOs participate in xenobiotic and drug metabolism; SOX mediates sulfur amino acid degradation and has emerged as a candidate diagnostic marker for HCC; and mARC functions in drug detoxification with potential therapeutic relevance in NAFLD and HCC.
Why it matters
Provides a consolidated mechanistic overview of the four known human molybdenum-dependent enzymes, outlining their relevance to drug metabolism and potential roles as diagnostic or therapeutic targets in liver disease.
Limits
As a narrative review, the paper provides no original empirical measurements, systematic search criteria, or meta-analytic pooling. Specific sensitivity and specificity metrics for SOX in HCC and exact clinical effect sizes are not reported in the abstract.
Cited by
- context Molybdenum acts as an antidote to counteract adverse reactions and hangover-like symptoms from sulfites and sulfur sensitivity.